Current report No. 16\/2022
Date prepared: June 22, 2022
Abbreviated name of the issuer: CELON PHARMA S.A.
Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodical information
Content of the report:
The Management Board of Celon Pharma S.A. (The \u201cCompany\u201d) informs that the Ordinary General Meeting (the \u201cOGM\u201d) of the Company held on June 22, 2022 adopted a resolution on coverage of loss and payment of the dividend for the financial year 2021. Under the resolution in question, the OGM decided that:
a) the Company’s net loss for the financial year starting on January 1, 2021 and ending on December 31, 2021 in the amount of PLN 11,606,054.98 will be covered by the part of the Company\u2019s supplementary capital created from the profit generated in the previous years.
b) the Company will pay out the dividend in the amount of PLN 0,29 per one share, which amounts to a total of PLN 14,798,700.00, whereas the amount of the recommended dividend will be paid out from the part of the Company’s supplementary capital created from the profit generated in the previous years and complies with the requirements of Article 348 of the Commercial Companies Code.
51,030,000 shares in the Company are covered by the dividend.
The Management Board set July 1, 2022 as the dividend record date, and for the dividend to be paid out on July 11, 2022.<\/p>\n","protected":false},"excerpt":{"rendered":"